Trials / Completed
CompletedNCT01631825
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 321 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
* To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study. * To investigate efficacy of SPM 962 in an exploratory manner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPM 962 | SPM 962 transdermal patch once a daily up to 36.0 mg/day |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-06-29
- Last updated
- 2014-03-19
- Results posted
- 2014-03-19
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01631825. Inclusion in this directory is not an endorsement.